You are here
Januvia (Sitagliptin) is an oral antidiabetic medicine belonging to class dipeptidyl peptidase-4 (DPP-4) inhibitor, manufactured by Merck & Co. The drug was approved by the U.S. Food and Drug Administration (FDA) in 2006 and is one of the most popular Type 2 diabetes drugs on the market. In 2007, the FDA approved a variation of Januvia called Janumet, which is a combination of sitagliptin and metformin, and is also made by Merck.
Sitagliptin is an anti-diabetic drug that works by increasing levels of natural substances called incretins. Incretins help to control blood sugar by increasing insulin release, especially after a meal. They also decrease the amount of sugar your liver makes. It works by regulating the levels of insulin your body produces after eating.
In 2011, the FDA received almost 200 reports of acute and chronic pancreatitis linked to Januvia some of which were fatal. In 2015, the FDA warned Januvia and Janumet could cause severe joint pain. The most serious injuries associated with Januvia are acute pancreatitis, pancreatic cancer and thyroid cancer.
Serious injuries associated with Januvia:
- Pancreatic Cancer
- Thyroid Cancer
- Acute Pancreatitis
- Hemorrhagic Pancreatitis
- Necrotizing Pancreatitis
- Severe Joint Ache
The U.S. Food and Drug Administration (FDA) warned that Type 2 diabetes drugs in the Dipeptidyl peptidase-4 (DPP-4) inhibitors class may cause severe joint pain.The FDA also warned about other side effects linked to DPP-4 inhibitors, including low blood sugar and inflammation of the pancreas known as pancreatitis.
Evidence to be looked for in potential cases
- 1. Usage of Januvia
- 2. Duration of Januvia usage
- 3. Indications for usage of Januvia
- 4. Complications and their treatment after Januvia Intake
Medical Record Review and claim validation of Januvia case should take approximately 3 hours in most instances; however, this approximation may vary in cases based on the volume of records.